Replies to post #137358 on Biotech Values

[mcbio]

Safety profile for the lower doses looks better as lymphocyte plateau reached by 12 weeks of treatment remained unchanged and vaccine challenge results were fine and infections were similar in the placebo. So immunosuppression beyond 24 weeks might be tolerated with the low doses.

Thanks genisi. Do you see this as a viable program for gout? Although the gout space is getting a bit crowded, this program does seem to be completely differentiated from the competition given MoA. And BCRX claims the drug has safety advantages compared to competitive agents in patients with kidney stones, which is up to 40% of the gout market I believe BCRX indicated. Hopefully BCRX will be able to land a partner to push it into Phase 3.

Separately, do you see a market opportunity for an oral HAE drug? BCRX plan to push their oral HAE drug into the clinic this year with the intention of keeping all rights to the drug should it reach the market.